Search Results

! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. GPCR Retreat Program < Back to schedule Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease Date & Time Friday, November 3rd / 9:20 AM Abstract Coming Soon About Ali Salahpour "Dr. Salahpour did his undergrad (1993-1996) and PhD (1996-2002) at University of Montreal in the Department of Biochemistry. His PhD work was under the supervision of Dr. Michel Bouvier working on the topic of GPCR dimerization/oligomerization. In November of 2002, he joined the lab of Dr. Marc Caron at Duke University for his post-doctoral training. In the Caron lab, Dr. Salahpour worked on Dopamine Transporter and its role on regulating dopamine transmission and homeostasis. In April 2009, he joined the Department of Pharmacology and Toxicology at University of Toronto and has continued working on dopamine transmission and homeostasis and the role of several of key modulators of the dopamine system, including the dopamine transporter (DAT), the Vesicular Monoamine Transporter 2 (VMAT2), Tyrosine Hydroxylase (TH) and Trace Amine Associate Receptor 1 (TAAR1)." Ali Salahpour on the web University of Toronto Pubmed Google Scholar Twitter Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Home → Flash News → Check out our #SpotifyWrapped 🚀! In 2024, Dr. GPCR reached listeners worldwide, sparking conversations about GPCRs with top experts. Thank you for tuning in! 📊🎙️ ✳️Check out our top episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-148-with-dr-arthur-christopoulos #gpcr #drgpcr Published on January 29, 2025 Category Check out our #SpotifyWrapped 🚀! In 2024, Dr. GPCR reached listeners worldwide, sparking conversations about GPCRs with top experts. Thank you for tuning in! 📊🎙️ ✳️Check out our top episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-148-with-dr-arthur-christopoulos #gpcr #drgpcr Previous Next Recent Articles

Home → Flash News → Let’s connect the dots! Update your Dr. GPCR profile to make meaningful connections in the global GPCR network 🌐 ✳️Visit https://www.ecosystem.drgpcr.com/account/my-account and fill out the boxes with your most updated information. #gpcr #drgpcr Published on January 8, 2025 Category Dr. GPCR Profiles Let’s connect the dots! Update your Dr. GPCR profile to make meaningful connections in the global GPCR network 🌐 ✳️Visit https://www.ecosystem.drgpcr.com/account/my-account and fill out the boxes with your most updated information. #gpcr #drgpcr Previous Next Recent Articles

Need help? Submit a problem! Get detailed information about incidents and find solutions. Join us today! Report an Incident Thank you for taking the time to report any incidents or issues you are experiencing with our site. Your comments will help us improve and refine the Ecosystem. Who is submitting this incident? First Name Last Name Email Details about this incident Please describe your concern Link to the page where you experienced difficulties Please feel free to upload screen shots or short videos of your concern. Upload File Upload supported file (Max 15MB) Submit Thanks for submitting!

GPCR Retreat Program < Back to schedule Breakfast 1 Date & Time Friday, November 3rd / 7:30 AM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

At Uppsala University, Jens Carlsson’s lab uses modeling to shape experiments—not just explain them. Discover how strategic collaboration drives real GPCR drug discovery impact. Home → Flash News → ep 175 with jens carlsson clip 2 If your model can’t change an experiment, what’s the point? Published on October 31, 2025 Category Dr. GPCR Podcast If your model can’t change an experiment, what’s the point? That’s the standard Dr. Jens Carlsson sets in his lab at Uppsala University. For him, modeling isn’t just about elegant simulations; it’s about impact . The kind of impact that shows up in how experiments are designed, which compounds get prioritized, and what gets synthesized next. Carlsson’s lab doesn’t work in isolation. They collaborate deeply with medicinal chemists, pharmacologists, and biotech partners to create workflows that connect virtual screening to synthesis and bioassay. Every step has a purpose. Every prediction feeds into a testable hypothesis. But the real differentiator? The way they collaborate: strategically, transparently, and without ego. His team is clear about the capabilities and limitations of their models, an honesty that builds long-term trust across disciplines. In GPCR drug discovery, where complexity is the rule and timelines are tight, this kind of cross-functional fluency is no longer optional. It’s the catalyst for turning insight into innovation. 🎧 Learn how Carlsson turns models into translational outcomes in this episode of the Dr. GPCR Podcast: model predict discover #DrGPCR #GPCR #CollaborationInScience #ComputationalChemistry #Pharmacology #DrugDesign Previous Next Recent Articles

Home → Flash News → ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery, you know that finding a promising candidate is just the start. A drug must also: ✅ Be absorbed into the body ✅ Reach the right target ✅ Stay long enough to be effective ✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Published on March 10, 2025 Category Dr. GPCR Courses ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery , you know that finding a promising candidate is just the start. A drug must also:✅ Be absorbed into the body✅ Reach the right target✅ Stay long enough to be effective✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Previous Next Recent Articles

Home → Flash News → ep 169 with sokhom pin some 3 Published on July 15, 2025 Category Dr. GPCR Podcast Stayed when others pivoted. Now leading the field. While others left GPCRs behind, Sokhom S. Pin stayed the course. From DuPont to Cerevel, he focused on GPCR biology and became one of the few deep experts still standing when the field surged back. Patience. Passion. Positioning. 🎧 Hear about the journey: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin #GPCRdrugdiscovery #GPCR #GPCRtrainingprogram #DrGPCR Previous Next Recent Articles

Discover our comprehensive legal policies and disclaimers for Dr. GPCR Ecosystem, ensuring transparency and protecting your rights. Legal Policies and Disclaimers These legal documents and the agreement on Terms of Service (the “ATS”) for our websites ( Ecosystem.DrGPCR.com and DrGPCR.com ) (the “Website” or "Websites"). By using our Website, you agree to fully comply with and be bound by the following ATS each time you use our Website. Please review the following terms carefully. Dr. GPCR, Corp (“Dr. GPCR” or "DrGPCR") provides its Service (as defined below) to you through our websites referred to as Dr. GPCR, Ecosystem.DrGPCR.com , DrGPCR.com . By accepting these Legal Policies and Disclaimers or by accessing or using the Service or Website, you acknowledge that you have read, understood, and agree to be bound by these Legal Policies and Disclaimers. If you are entering into this ATS on behalf of a company, business, or other legal entity, you represent that you have the authority to bind such entity and its affiliates to this ATS. If you do not have such authority, or if you do not agree with this ATS, you must not accept this ATS and may not use the Service. Dr. GPCR reserves the right to modify these Legal Policies and Disclaimers from time to time without prior notice. You can review the most current versions at any time on our Website. The revised terms and conditions will take effect upon posting. If you use the Service after this date, your continued use will constitute acceptance of the revised conditions. If any change to these Legal Policies and Disclaimers is not acceptable to you, stop accessing and using the Service. These agreements contain warranty disclaimers and other provisions that limit our liability to you. Please read these Legal Policies and Disclaimers carefully and in their entirety, as using, accessing, and/or browsing our Website constitutes acceptance of these terms and conditions. If you do not agree to be bound to each and every term and condition set forth herein, please exit our website immediately and do not use access and/or access it further. These Legal Policies and Disclaimers below must be accepted as a whole. You cannot accept one and ignore the others. Please read carefully our Legal Policies and Disclaimers to understand how Dr. GPCR conducts business Affiliate Policy Content and Conduct Policy Content Guidance Privacy Policy Terms and Conditions Trademark Policy

< Back This is a Title 01 This is placeholder text. To change this content, double-click on the element and click Change Content. This is placeholder text. To change this content, double-click on the element and click Change Content. Want to view and manage all your collections? Click on the Content Manager button in the Add panel on the left. Here, you can make changes to your content, add new fields, create dynamic pages and more. You can create as many collections as you need. Your collection is already set up for you with fields and content. Add your own, or import content from a CSV file. Add fields for any type of content you want to display, such as rich text, images, videos and more. You can also collect and store information from your site visitors using input elements like custom forms and fields. Be sure to click Sync after making changes in a collection, so visitors can see your newest content on your live site. Preview your site to check that all your elements are displaying content from the right collection fields. Previous Next News Get in Touch Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About

< Back This is a Title 02 This is placeholder text. To change this content, double-click on the element and click Change Content. This is placeholder text. To change this content, double-click on the element and click Change Content. Want to view and manage all your collections? Click on the Content Manager button in the Add panel on the left. Here, you can make changes to your content, add new fields, create dynamic pages and more. You can create as many collections as you need. Your collection is already set up for you with fields and content. Add your own, or import content from a CSV file. Add fields for any type of content you want to display, such as rich text, images, videos and more. You can also collect and store information from your site visitors using input elements like custom forms and fields. Be sure to click Sync after making changes in a collection, so visitors can see your newest content on your live site. Preview your site to check that all your elements are displaying content from the right collection fields. Previous Next News Get in Touch Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Coffee Break with lights snacks Complimentary < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Session VIII * Physiological and pathological roles of AGPCRs in the periphery The CELSR/ADGRC Homolog Flamingo Is Not Autoproteolytically Processed By The GAIN Domain Tobias Langenhan Characterization of Phenotypes Associated with GPR110 Deletion Hee-Yong Kim The Adhesion GPCR Cupidon Regulates Mating In The Closest Relatives Of Animals Alain Garcia De Las Bayonas Critical role for CD97/ADGRE5 in the induction of allergic airway inflammation Gabriela Aust The CELSR/ADGRC Homolog Flamingo Is Not Autoproteolytically Processed By The GAIN Domain Tobias Langenhan Abstract Only available for AGPCR 24 Attendees Authors & Affiliations "Tobias Langenhan, Nicole Scholz, Genevieve M. Auger, Helen Strutt, David Strutt" About Tobias Langenhan "1997-2004: Medical school and Dr. med. Neuroanatomy (Würzburg, Germany); 2004-2005: M.Sc. Neuroscience (Oxford, UK); 2005-2009: D.Phil. Neuroscience (Oxford, UK); 2009-2016: Group leader, Institute of Neurophysiology (Würzburg, Germany); 2016: Heisenberg professorship (Würzburg, Germany); 2016-to date: Professor and Chair in Biochemistry (Leipzig, Germany)" Tobias Langenhan on the web Langenhan Lab LinkedIn Characterization of Phenotypes Associated with GPR110 Deletion Hee-Yong Kim Abstract "G-protein coupled receptor 110 (ADGRF1, GPR110), an adhesion GPCR recently deorphanized, plays an important role in in the development of neurons and cognitive function. Synaptamide, an endogenous ligand for GPR110, binds to the N-terminal G-protein autoproteolysis-inducing (GAIN) domain of GPR110, and activates GPR110/cAMP signaling. This activation promotes neurogenic differentiation of neural stem cells, neurite growth, and synaptogenesis of developing neurons. In addition, a significant role of GPR110 in blood brain barrier (BBB) function has been discovered. GPR110 is highly expressed in mouse and human NPCs and neurons, while its expression was absent in astrocytes. GPR110 is also highly expressed in the kidney, however, little is known about the function of this receptor in renal physiology. To extend our understanding of the role of GPR110 signaling in kidney, we evaluated the urine albumin level in mice devoid of GPR110 gene (GPR110 KO) compared to the wild type (WT). To provide the molecular basis for the renal phenotype, we analyzed in parallel differential expression of kidney proteins in GPR110 KO and WT mice by label-free LC-MS/MS and pathway analysis. We found that the albumin to creatinine ratio was significantly elevated in urine samples obtained from GPR110 KO mice, indicating glomerular filtration dysfunction. The change in protein expression of key proteins including VEGFA is associated with the abnormal renal phenotype of albumin urea in GPR110 KO mice. In addition to the central nervous system phenotype such as learning and memory deficit and BBB dysfunction, our study revealed a new renal phenotype associated with lack of GPR110 signaling. " Authors & Affiliations "Laboratory of Molecular Signaling, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, USA" About Hee-Yong Kim "Senior Investigator and Chief of the Laboratory of Molecular Signaling at NIAAA, NIH" Hee-Yong Kim on the web NIH The Adhesion GPCR Cupidon Regulates Mating In The Closest Relatives Of Animals Alain Garcia De Las Bayonas Abstract "All animals develop through the recognition, adhesion, and fusion of a differentiated sperm and egg. Although fundamental, the evolution of gametogenesis and fertilization in animals is poorly understood. Recently, evidence for sex has been described in choanoflagellates, the closest living relatives of animals. Under nutrient depletion, the model choanoflagellate Salpingoeca rosetta forms distinct cell types that aggregate, fuse, and undergo meiotic recombination. Additionally, the bacterium Vibrio fischeri also induces mating in S. rosetta cultures, suggesting that multiple environmental cues can trigger sex. Importantly, the signaling pathways underlying sexual reproduction in these different contexts have not been investigated. In this study, we report the discovery of an adhesion GPCR, named Cupidon, that regulates the switch from vegetative growth to sexual reproduction in S. rosetta. We found that the knock-out of cupidon induces a gain in cell adhesion and cell fusion, resembling the mating behavior of wild-type cells under nutrient depletion. Cupidon mutants, similar to starved wild-type cells, upregulate various extracellular matrix-related genes, including teneurins and metalloproteases. Finally, we showed that nutrient availability controls the dissociation of the N-terminal fragment in Cupidon. Together, our results suggest that Cupidon prevents sexual reproduction in S. rosetta under high nutrient availability, by inhibiting genes involved in gamete recognition. " Authors & Affiliations "King Nicole, Howard Hughes Medical Institute and Department of Molecular and Cell Biology, University of California Berkeley" About Alain Garcia De Las Bayonas "Hi everyone! I am currently finishing my postoc in the laboratory of Pr Nicole King at UC Berkeley where I am studying the evolution of GPCR families in choanoflagellates, the sister group of animals. I have a particular interest in understanding the premetazoan function of adhesion GPCRs." Alain Garcia De Las Bayonas on the web King Lab Critical role for CD97/ADGRE5 in the induction of allergic airway inflammation Gabriela Aust Abstract Only available for AGPCR 24 Attendees Authors & Affiliations Coming Soon About Gabriela Aust Coming Soon Gabriela Aust on the web Coming Soon < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Plenary Lecture Identification and Functional Characterization of Adhesion GPCRs As Steroid Hormone Receptors and Hearing and Balance Receptors Abstract Only Available for AGPCR24 Attendees About Jin-Peng Sun "Since starting my laboratory in 2011, I has focused on G protein coupled receptors, in particular, the ligand identification, physiological functions and molecular mechanism of biased signaling of GPCRs. Our first main research aspect is the identification of endogenous ligand of GPCRs. We have identified the receptor subfamily to sense the steroid hormones. For instance, membrane receptor GPR97 is able to sense glucocorticoid to mediate its rapid actions, the progesterone and 17-hydroxyprogesterone membrane receptor are GPR126. We also identified DHEA, DHEAS and DOC are endogenous ligands of GPR64 etc (Nature, 2021a, Nat Chem Biol 2022, PNAS 2022b). Our second main research aspect is dissecting the molecular mechanism underlying sensation of force, ordor, itch and taste by GPCRs. We have elucidated the mechanism of receptors' perception of itch, olfactory and force (Nature 2021b, 2022a, 2022b, 2023a, 2024). Our third main research aspect is working mechanism of GPCR. For arrestin mediated biased signaling, we have proposed the “flute model” and “poly proline region docking theory” etc. to explain the arrestin mediated GPCR functions (Nature communications, 2015, 2021, 2022; PNAS 2021, Molecular Pharmacology, 2017; Recommended by Faculty 1000, Nature Chemical Biology 2018). We identified that arrestin can mediated AT1R/TRPC3 or M3R/TRPC3 coupling by forming a complex of AT1R/β-arrestin-1/PLCγ/TRPC3 or M3R//β-arrestin-1/TRPC3 (Nature communications, 2017, Nature communications, 2018). We also identified that orphan receptor GPR64 forms complex with β-arrestin-1 and CFTR at apical membrane of efferent ductulus to regulate the salt/water metabolism (eLife 2018, Faculty 1000 recommendation). Our fourth main research aspect is ligand coding mechanisms and structural aided drug discovery of GPCR. We have decoded the mechanisms underlying recognition of fish oil (unsaturated fatty acids) and other lipids by GPCRs (Science 2023, Science Advance 2021, PNAS 2023, Nature Metabolism 2023), recognition of amine containing hormones by GPCRs (Cell 2021, 2023, Nature 2023b), bile acids or its derivatives by GPCRs (Nature 2020)." Jin-Peng Sun on the web Google Scholar LinkedIn < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Coffee Break with pastries announcement of the aGEM award Complimentary < Previous Session Next Session >

Discover the power of partnership with GPCR Retreat-Sponsors, the backbone of our event. Explore our dedicated Sponsors page today! Retreat 2023 About Program Registration Logo Contest Committee Sponsors Sponsors Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Coffee Break 1 Date & Time Thursday, November 2nd / 2:45 PM Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Board meeting/General assembly Welcome to Join Coming Soon < Previous Session Next Session >

Submit your abstract for the Adhesion GPCR Workshop 2024. Share your research, connect with experts, and be part of the leading GPCR scientific community. ABSTRACT SUBMISSION Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Submit your Abstract Here Abstracts configuration 1. Abstract category (oral presentations) 2. Title: Capitalize each word, 20 words max, Bold 3. Authors’ names in full: Last name, First name 4. Institutions 5. Abstract body 6. Funding source Oral presentations Extended deadline: August 1st Speaker name indicated in bold and underlined Indicate abstract category on top left corner (up to 2 categories max) Abstract categories Signaling Trafficking Metabolism Structure and Bioinformatics Health and Disease Immunology Nervous system Model Organism Phylogenetics and Evolution Aging Basic and Clinical Pharmacology Proteomic and Transcriptomics Biosensors and Molecular Tools Biomarkers Poster presentations Deadline: August 1 The presenter's name is indicated in bold and underlined Poster size Poster width: 90 cm max Poster height: 140 cm max Register for the Adhesion GPCR 2024 [ Registration extended until September 15th ] Learn more about the Adhesion GPCR workshop 2024 Up About the event Learn more about the Adhesion GPCR Workshop 2024 and its preliminary program. Up About the venue Discover Cinvestav, the host venue for the upcoming workshop. Up Traveling Tips Find essential tips about Mexico City, including transportation options and local insights. Up Logo Contest Enter our logo contest for a chance to have your design represent the upcoming event.

Explore Terry’s Pharmacology Vault. Master irreversible kinetics, target depletion, and structured tissue penetration in real drug discovery contexts. Home → Flash News → irreversible drugs post 3 Irreversible kinetics = strategic lever in drug design. Published on October 27, 2025 Category Terry's Corner Receptor pharmacology has evolved. Irreversible interactions are no longer niche curiosities — they’re strategic levers that shape how molecules behave in vivo and whether candidates advance or stall in discovery. Inside Terry’s Corner, you’ll gain access to focused, high-impact modules built for teams who need to engineer binding kinetics, not just potency . These lessons bridge molecular pharmacology with real-world design strategy, giving discovery teams the tools to make smarter decisions earlier in the pipeline. Here’s what’s covered in this week’s lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic durability, and influence dosing intervals. Structured tissue penetration challenges — why high-affinity molecules stall at the periphery and how to optimize kinetic profiles for deeper reach. Quantifying irreversible activity (K_inact / K_I) — turning persistent binding into measurable design parameters that guide candidate optimization. Join to learn the same principles guiding successful drug programs today. 🟢 Browse the full video vault and stay ahead of the curve: ✳️ Courses by Terry | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #DrugDiscovery #Kinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDevelopment Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Join Terry’s Corner AMA to master GPCR signaling, allosteric modulation, and kinetic strategy in drug discovery. Level up your pharmacology toolkit. Home → Flash News → ama session sept 18 post 1 Ask-Me-Anything Session - Sept 18 - Trailer Published on October 28, 2025 Category Terry's Corner Pharmacology doesn’t stand still—and neither should your toolkit. In the discovery phase, one overlooked kinetic parameter or a misjudged model can set your team back months . Precision in early decisions determines whether your molecule moves forward or stalls. That’s why we’ve built a dedicated space inside Terry’s Corner to get clear, evidence-based answers to the questions that shape your experiments and strategy. In this AMA session, you’ll learn how to: Decode GPCR signaling complexity using functional assay strategies Identify allosteric modulators before they derail downstream decisions Integrate kinetics early—before your program locks into costly pathways Rethink legacy screening frameworks through modern pharmacology This isn’t theory. It’s 45+ years of applied discovery experience from Terry Kenakin distilled into practical, modular lessons designed for scientists who need clarity fast. 🟢 Join Terry’s Corner → Terry's Corner | Dr. GPCR Ecosystem ✳️ BONUS — Live AMA Session: Get direct, unfiltered access to Terry. Bring your most challenging questions to our next Ask Me Anything session on October 30, 12–1 PM EST . ⚠️ Seats are limited. Don’t fall behind on what will shape the next decade of discovery. #GPCR #DrGPCR #Pharmacology #DrugDiscovery #Biotech #AllostericModulation #Kinetics #AssayDevelopment #EarlyDiscovery #PharmaR&D #BiotechInnovation Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

A breakthrough in GPCR imaging reveals a full native pancreatic islet and advances how GLP-1R can be visualized in tissue using chemical probes. Home → Flash News → Lighting up a native pancreatic islet isn’t just a technical win it’s a shift in what GPCR imaging can reveal Lighting up a native pancreatic islet isn’t just a technical win — it’s a shift in what GPCR imaging can reveal Published on December 8, 2025 Category Our latest Dr. GPCR blog breaks down the moment Dr. Johannes Broichhagen and David Hodson realized their fluorescent peptide probe could visualize GLP-1R across an entire intact islet — not in an overexpression system, but in real tissue. This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor biology: Higher fidelity GPCR imaging without antibody variability Surface-pool selectivity — the pharmacologically relevant population Compatibility with live cells, tissue, and deep-imaging setups A design logic that extends to other GPCRs Just as important: the collaboration model behind the science.Trust, interdisciplinary thinking, and a shared drive to build tools that actually work at the bench. If your team relies on receptor visualization — discovery, screening, translational work — this story has strategic takeaways you’ll want to steal. 🔗 Read the blog : https://www.ecosystem.drgpcr.com/post/when-the-islet-lit-up-advancing-gpcr-imaging-in-native-tissue #GPCR #DrGPCR #GPCRimaging #biotech #drugdiscovery Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

< Back This is a Title 03 This is placeholder text. To change this content, double-click on the element and click Change Content. This is placeholder text. To change this content, double-click on the element and click Change Content. Want to view and manage all your collections? Click on the Content Manager button in the Add panel on the left. Here, you can make changes to your content, add new fields, create dynamic pages and more. You can create as many collections as you need. Your collection is already set up for you with fields and content. Add your own, or import content from a CSV file. Add fields for any type of content you want to display, such as rich text, images, videos and more. You can also collect and store information from your site visitors using input elements like custom forms and fields. Be sure to click Sync after making changes in a collection, so visitors can see your newest content on your live site. Preview your site to check that all your elements are displaying content from the right collection fields. Previous Next News Get in Touch Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About

Home → Flash News → New Episode Alert! 🎙️ Ep. 163 of the Dr. GPCR Podcast is here! 🚀 This time, we sit down with Dr. Dmitry Veprintsev to discuss the importance of asking the right GPCR questions. Whether you're a researcher, student, or GPCR enthusiast, this episode is packed with insights that will challenge how you think about your experiments. ✳️Tune in at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #Biotech #GPCRs Published on April 1, 2025 Category Dr. GPCR Podcast New Episode Alert! 🎙️ Ep. 163 of the Dr. GPCR Podcast is here! 🚀 This time, we sit down with Dr. Dmitry Veprintsev to discuss the importance of asking the right GPCR questions. Whether you're a researcher, student, or GPCR enthusiast, this episode is packed with insights that will challenge how you think about your experiments. ✳️Tune in at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #Biotech #GPCRs Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Home → Flash News → Generic tools won’t solve tomorrow’s drug discovery challenges. That’s why Celtarys designs custom fluorescent probes for every target, built for real pharmacology, not just convenience. With Dr. GPCR and Celtarys joining forces, expect more visibility, more precision, and more scientific impact. 🚀 Get to know our media partner: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #GPCRdrugDiscovery #GPCRecosystem #CustomLigands Published on June 27, 2025 Category Celtarys - Media Partner Generic tools won’t solve tomorrow’s drug discovery challenges. That’s why Celtarys designs custom fluorescent probes for every target, built for real pharmacology, not just convenience. With Dr. GPCR and Celtarys joining forces, expect more visibility, more precision, and more scientific impact. 🚀 Get to know our media partner: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #GPCRdrugDiscovery #GPCRecosystem #CustomLigands Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Stay informed and accountable with our comprehensive Content and Conduct Policy. Join Dr. GPCR Ecosystem and promote a positive online community. Content and Conduct Policy Dr. GPCR, Corp, LLC (“Dr. GPCR”) provides its Service to you through our websites referred to as Dr. GPCR, Ecosystem.DrGPCR.com, DrGPCR.com. We rely heavily on users to report content that may violate our policies. After we are notified of a potential policy violation, we may review the content and take action, including restricting access to the content, removing the content, and limiting or terminating a user’s access to Ecosystem.DrGPCR.com products. Note that we may make exceptions to these policies based on artistic, educational, or documentary considerations or when there are other substantial benefits to the public from not taking action. We respect the freedom of speech. Please note that Ecosystem.DrGPCR.com is specializes in GPCR and related subjects. We occasionally modify these policies, so please check back here for updates. Beyond the guidelines listed below, please note that several products and features may have additional policies and terms; check the provided links for those specific requirements. Responsibility for Your Content You are solely responsible for Your Content, and once published, it may not always be withdrawn. You assume all risks associated with Your Content, including anyone's reliance on its quality, accuracy, or reliability, or any disclosure by you of information in Your Content that makes you personally identifiable. You represent that you own or have the necessary permissions to use and authorize your Content as described herein. You may not imply that Your Content is in any way sponsored or endorsed by Ecosystem.DrGPCR.com. You may expose yourself to liability if, for example, Your Content contains material that is false, intentionally misleading, or defamatory; violates any third-party right, including any copyright, trademark, patent, trade secret, moral right, privacy right, right of publicity, or any other intellectual property or proprietary right; contains unlawful material, including illegal hate speech or pornography; exploits or otherwise harms minors, or violates or advocates the violation of any law or regulation. Our Right to Use Your Content You also give Ecosystem.DrGPCR.com (Website) a perpetual, irrevocable, worldwide, royalty-free, and non-exclusive license to reproduce, adapt, modify, translate, publish, publicly perform, publicly display, distribute, store and create derivative works of the basic listing information about your entity that you provide to your Ecosystem.DrGPCR.com Account (such as the entity name, location, phone number, list of interest, business category, hours, services, product descriptions, text, videos, contents, and website) We may use Your Content in several different ways, including publicly displaying it, reformatting it, incorporating it into advertisements and other works, creating derivative works from it, promoting it, distributing it, and allowing others to do the same in connection with their websites and media platforms ("Other Media"). As such, you at this moment irrevocably grant us worldwide, perpetual, non-exclusive, royalty-free, assignable, sub-licensable, transferable rights to use Your Content for any purpose. Please note that you irrevocably grant the users of the Site and any Other Media the right to access Your Content in connection with their use of the Site and any Other Media. Finally, you irrevocably waive and cause to be waived against Ecosystem.DrGPCR.com and its users any claims and assertions of moral rights or attribution with respect to Your Content. By "use" we mean use, copy, publicly perform and display, reproduce, distribute, modify, translate, remove, analyze, commercialize, and prepare derivative works of Your Content. Ownership Between you and Ecosystem.DrGPCR.com, you own Your Content. We own the Ecosystem.DrGPCR.com Content, including but not limited to visual interfaces, interactive features, graphics, design, compilation, including, but not limited to, our compilation of User Content and other Site Content, computer code, products, software, aggregate user review ratings, and all other elements and components of the Site excluding Your Content, User Content and Third Party Content. We also own the copyrights, trademarks, service marks, trade names, and other intellectual and proprietary rights throughout the world ("IP Rights") associated with the Ecosystem.DrGPCR.com Content and the Site, which are protected by copyright, trade dress, patent, trademark laws and all other applicable intellectual and proprietary rights and laws. As such, you may not modify, reproduce, distribute, create derivative works or adaptations of, publicly display or in any way exploit any of the Ecosystem.DrGPCR.com Content in whole or in part except as expressly authorized by us. Except as expressly and unambiguously provided herein, we do not grant you any express or implied rights, and we retain all rights in and to the Site and the Ecosystem.DrGPCR.com Content. Advertising Ecosystem.DrGPCR.com and its licensees may publicly display advertisements and other information adjacent to or included with Your Content. You are not entitled to any compensation for such advertisements. The manner, mode, and extent of such advertising are subject to change without specific notice to you. Content We make some of the Ecosystem.DrGPCR.com Site Content available to third parties. You may access and use these content in order to display on your personal computer, website, or blog ("Your Site"), provided that (i) your use of the Feeds is for personal, non-commercial purposes only, (ii) your display of the Feed Content links back to the relevant pages on Ecosystem.DrGPCR.com Website's websites, and attributes Ecosystem.DrGPCR.com as the source of the Content, (iii) your use or display of the Content does not suggest that Ecosystem.DrGPCR.com promotes or endorses any third party causes, ideas, websites, products or services, including Your Site, (iv) you do not redistribute the Content, and (v) your use of the Content does not overburden Ecosystem.DrGPCR.com Website’s systems. Ecosystem.DrGPCR.com reserves all rights in the Content and may terminate the Content at any time. Other User Content (including any that may have been created by users employed or contracted by the Ecosystem.DrGPCR.com Website) does not necessarily reflect the opinion of Ecosystem.DrGPCR.com. We reserve the right to remove, screen, edit, or reinstate User Content at our sole discretion, for any reason or no reason, and without notice to you, from time to time. For example, we may remove a review if we believe it violates our Content Guidelines. We have no obligation to retain or provide you with copies of Your Content, nor do we guarantee any confidentiality with respect to Your Content. Illegal Activities Do not use our Services to engage in illegal activities or promote dangerous and illegal acts. Malicious and Deceptive Practices Do not transmit viruses, malware, or any other malicious or destructive code. Do not distribute content that harms or interferes with the operation of the networks, servers, or other infrastructure of Ecosystem.DrGPCR.com or others. Do not use our Services for phishing scams. Hate Speech Our products are platforms for free expression. But we don't support content that promotes or condones violence against individuals or groups based on race or ethnic origin, religion, disability, gender, age, nationality, veteran status, or sexual orientation/gender identity, or whose primary purpose is inciting hatred on the basis of these core characteristics. This can be a delicate balancing act, but if the primary purpose is to attack a protected group, the content crosses the line. Personal and Confidential Information Do not distribute other people’s personal and confidential information, such as credit card numbers, confidential national ID numbers, or account passwords, without their permission. Do not post or distribute images or videos of minors without the necessary consent from their legal representatives. Account Hijacking Do not access another user’s account without their permission. Child Exploitation Do not upload or share content that exploits or abuses children. This includes all child sexual abuse imagery (even cartoon images or videos) and all content that presents children in a sexual manner. We will remove such content and take appropriate action, which may include disabling accounts and reporting to the National Center for Missing & Exploited Children (NCMEC) and law enforcement. Note that this policy may additionally apply to any content uploaded or transmitted through Photos or Videos. If you find any content that you think exploits children in this manner, do not share or comment on such content, even if your intent is to bring it to Ecosystem.DrGPCR.com's attention. Instead, flag the content. If you find content elsewhere on the internet, please contact NCMEC directly. Spam Do not spam, including by sending unwanted promotional or commercial content, or mass solicitations. Do not aggressively follow people or aggressively message people that you do not know. Ranking Manipulation Do not manipulate rankings or relevancy using techniques such as repetitive or misleading keywords or metadata. Sexually Explicit Material Do not distribute sexually explicit or pornographic material. Do not drive traffic to commercial pornography sites. Note that your profile photo cannot include mature or offensive content. For example, do not use a photo that is a close-up of a person’s buttocks or cleavage. Harassment, Bullying, and Threats Do not engage in harassing, bullying, or threatening behavior, and do not incite others to engage in these activities. Anyone using our Services to single someone out for malicious abuse, to threaten someone with serious harm, to sexualize a person in an unwanted way, or to harass in other ways may have the offending content removed or be permanently banned from using the Services. In emergency situations, we may escalate imminent threats of serious harm to law enforcement. Keep in mind that online harassment is also illegal in many places and can have serious offline consequences for both the harasser and the victim. Violence Do not distribute depictions of graphic or gratuitous violence. Impersonation Do not use our Services to mislead or confuse users by pretending to be someone else or pretending to represent an organization you do not represent. Regulated Goods and Services Your content cannot promote regulated goods and services, including but not limited to alcohol, gambling, unapproved supplements, tobacco, fireworks, or weapons. If we receive a complaint that such content violates applicable laws and regulations, we will remove and delete the offending content or account. Contests and Promotions Ecosystem.DrGPCR.com allows contests, sweepstakes, and other promotions ("Promotions") to the extent permitted by law, subject to the following policy requirements and legal terms outlined below. 1. Generating spam or encouraging individuals to engage in spam or abuse is strictly prohibited. Please note that the definition of spam on Ecosystem.DrGPCR.com may develop and change over time, and that Ecosystem.DrGPCR.com reserves the right to determine what qualifies as spam. In order to play a part in helping us fight spam and abuse, we have the following specific requirements for Promotions: 1a. The official rules for your Promotion must include a clear statement that anyone found to have created multiple accounts in order to increase their chances of winning, or anyone who posts entries in excess of an entry limit you have set, will be disqualified from the Promotion. You must set an entry limit for your promotion below a level that is likely to encourage spam. 1b. If you ask participants to use tags and/or hashtags in their Promotion entries, they must be relevant to the kind of content users are posting. For example, do not ask for photos of sunsets with #spaghetti. 2. Promotions should not be used to try to circumvent any applicable terms or policies. 3. Do not run Promotions that offer potential rewards in exchange for sharing content, following a user, mentioning a user (other than the contest creator, sponsor, or an affiliate of the contest creator or sponsor), having other users enter the promotion, or voting in polls. Also, avoid running promotions that encourage users to post unoriginal or repetitive content. 4. Please note that doing a public search (via hashtag or otherwise) may not show every entry or every participant in your Promotion. Accordingly, you should not rely solely on the search feature to view or find all entries or participants in your Promotion. 5. Please note that some Promotion entries may be filtered, hidden, or removed from Ecosystem.DrGPCR.com for spam or quality reasons, or any of our other applicable policies or terms of service. Use of Multiple Accounts Do not create or use multiple accounts to evade our policies or bypass blocks or otherwise subvert restrictions placed on your account. For example, if you’ve been blocked by another user or suspended for abuse, don’t create a replacement account that engages in similar activity. Please read carefully our Legal Policies and Disclaimers to understand how Dr. GPCR conducts business Affiliate Policy Content and Conduct Policy Content Guidance Privacy Policy Terms and Conditions Trademark Policy

Discover how low-offset kinetics reshape drug efficacy. Join Terry’s Corner and master irreversible pharmacology for modern discovery programs. Home → Flash News → irreversible drugs post 1 Irreversible Drugs – Trailer Published on October 21, 2025 Category Terry's Corner Irreversible drugs change the rules of engagement. Unlike reversible ligands, their impact can persist long after the compound is gone — creating durable pharmacological effects that reshape how pharmacokinetics and pharmacodynamics intersect. In modern discovery programs, that’s a decisive advantage (or a hidden liability) in candidate selection. In this week’s lesson, you’ll unpack: Why low offset rates can mimic covalent effects without forming actual bonds. How target depletion and replenishment kinetics define the therapeutic window. How persistent binding alters structured tissue penetration — and why that matters for tumor targeting and beyond. These tactical frameworks are used to optimize molecules, sharpen PK/PD strategy, and mitigate downstream safety surprises before they appear in IND-enabling studies. Understanding irreversible interactions can mean the difference between a stalled program and a strategic breakthrough. Those who master kinetic pharmacology set the pace. 🟢 Join Terry’s Corner and sharpen your pharmacology toolkit. ✳️ Terry's Corner | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #DrugDiscovery #MedicinalChemistry #PKPD #ReceptorKinetics #DrugDevelopment Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Home → Flash News → Did you know? 🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! 🧬💡 These innovative compounds, “Photo-BQCisA” and “Photo-BQCtrAns,” offer subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic strategies targeting muscarinic receptors (M1-M5). 🔬✨ Learn more about this breakthrough in the Ecosystem! Published on December 3, 2024 Category GPCR Weekly News Did you know? 🌟 Researchers have developed reversibly photoswitchable allosteric modulators for Class A GPCRs! 🧬💡 These innovative compounds, “Photo-BQCisA” and “Photo-BQCtrAns,” offer subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic strategies targeting muscarinic receptors (M1-M5). 🔬✨ Learn more about this breakthrough in the Ecosystem! ➡️ buff.ly/4fgX4ZH #gpcr #drgpcr Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025

Join the forefront of GPCR research at the Dr. GPCR Summit! Embracing innovation and technology, we connect global scientific communities. Experience talks spanning time zones, with options for live or pre-recorded presentations. Uncover groundbreaking insights in GPCR science together. Learn more. Dr. GPCR Summit We live in a new world, and we think it's an opportunity to try new things and use current technologies to help us connect and spread scientific advances in the GPCR field. Our goal is to allow everyone in the GPCR community to get access to the talks through the entire length of the event independently of their time zone. This means that presenters will have the option of providing a pre-recorded talk or giving a live presentation. More information is outlined below. See Schedule See Schedule See Schedule

Home → Flash News → Did you know that GPR180 helps regulate lipid metabolism and may play a role in preventing obesity? recent study shows that overexpression of GPR180 in adipose tissue improves lipid metabolism and protects against HFD-induced obesity, while its knockout worsens lipid accumulation. This finding highlights GPR180 as a potential therapeutic target for metabolic disorders! Catch up on this exciting research in the Ecosystem today! 🏆📖 You’ll need to register, but don’t worry—it’s free! ➡️https://www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/gpr180-reduces-adiposity-by-inhibiting-lipogenesis-and-fatty-acid-uptake-in-adipocytes #gpcr #drgpcr #metabolism #obesity Published on March 3, 2025 Category GPCR Weekly News Did you know that GPR180 helps regulate lipid metabolism and may play a role in preventing obesity? recent study shows that overexpression of GPR180 in adipose tissue improves lipid metabolism and protects against HFD-induced obesity , while its knockout worsens lipid accumulation . This finding highlights GPR180 as a potential therapeutic target for metabolic disorders! Catch up on this exciting research in the Ecosystem today! 🏆📖 You’ll need to register, but don’t worry—it’s free ! ➡️ https:// www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/gpr180-reduces-adiposity-by-inhibiting-lipogenesis-and-fatty-acid-uptake-in-adipocytes #gpcr #drgpcr #metabolism #obesity Previous Next Recent Articles Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris 5 days ago The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025 Scientific Isolation: The Real Reason Early Biotechs Lose Traction The Quiet Drift You Don’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts clicking… and the company quietly stops doing anything else. BD conversations stay warm but motionless. Investor updates become thinner. Internal meetings slowly morph into scientific colloquia instead of decision-making forums. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. No drama. No blow-ups.Just Attila Foris Dec 17, 2025 Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls Binding affinity appears straightforward: add ligand, measure signal, fit a curve. Yet discovery teams routinely lose time and misallocate resources because the underlying biology behaves nothing like the idealized systems we learned in textbooks. GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry and time. The result is a recurring pattern across programs—clean data that is not actually telling the truth. Orthosteric bi Terry's Desk Dec 16, 2025